Article Versions Notes

Lamure S, Van Laethem F, De Verbizier D, Lozano C, Gehlkopf E, Tudesq J-J, Serrand C, Benzaoui M, Kanouni T, Quintard A, et al. Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers. 2021; 13(17):4279. https://doi.org/10.3390/cancers13174279

Lamure, Sylvain, François Van Laethem, Delphine De Verbizier, Claire Lozano, Eve Gehlkopf, Jean-Jacques Tudesq, Chris Serrand, Mehdi Benzaoui, Tarik Kanouni, Adeline Quintard, and et al. 2021. "Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy" Cancers 13, no. 17: 4279. https://doi.org/10.3390/cancers13174279

Lamure, S., Van Laethem, F., De Verbizier, D., Lozano, C., Gehlkopf, E., Tudesq, J.-J., Serrand, C., Benzaoui, M., Kanouni, T., Quintard, A., De Vos, J., Tchernonog, E., Platon, L., Ayrignac, X., Ceballos, P., Sirvent, A., François, M., Guedon, H., Quittet, P., ... Cartron, G. (2021). Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy. Cancers, 13(17), 4279. https://doi.org/10.3390/cancers13174279